These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38580564)

  • 1. Elexacaftor/Tezacaftor/Ivacaftor use in Pediatric Cystic Fibrosis Patients with Advanced Liver Disease.
    Protich HE; Molleston JP; Bozic M; Pettit RS
    J Cyst Fibros; 2024 Apr; ():. PubMed ID: 38580564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations in the fecal microbiota in patients with advanced cystic fibrosis liver disease after 6 months of elexacaftor/tezacaftor/ivacaftor.
    Duong JT; Pope CE; Hayden HS; Miller C; Salipante SJ; Rowe SM; Solomon GM; Nichols D; Hoffman LR; Narkewicz MR; Green N
    J Cyst Fibros; 2024 May; 23(3):490-498. PubMed ID: 38448281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis with the N1303K mutation: Case report and review of the literature.
    Tupayachi Ortiz MG; Baumlin N; Yoshida M; Salathe M
    Heliyon; 2024 Mar; 10(5):e26955. PubMed ID: 38463894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of CFTR mutations in people with cystic fibrosis and severe liver disease who are not eligible for CFTR modulators.
    Colombo C; Ramm GA; Lindblad A; Corti F; Porcaro L; Alghisi F; Asherova I; Evans H; Kashirskaya N; Kondratyeva E; Lewindon PJ; de Monestrol I; Oliver M; Ooi CY; Padoan R; Shankar S; Alicandro G
    J Cyst Fibros; 2023 Mar; 22(2):263-265. PubMed ID: 36739240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal changes in habitual physical activity in adult people with cystic fibrosis in the presence or absence of treatment with elexacaftor/tezacaftor/ivacaftor.
    Gruber W; Stehling F; Blosch C; Dillenhoefer S; Olivier M; Brinkmann F; Koerner-Rettberg C; Sutharsan S; Mellies U; Taube C; Welsner M
    Front Sports Act Living; 2024; 6():1284878. PubMed ID: 38463712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the
    Carnovale V; Iacotucci P; Terlizzi V; Colangelo C; Ferrillo L; Pepe A; Francalanci M; Taccetti G; Buonaurio S; Celardo A; Salvadori L; Marsicovetere G; D'Andria M; Ferrara N; Salvatore D
    J Clin Med; 2022 Feb; 11(4):. PubMed ID: 35207295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of transaminitis in adults with cystic fibrosis taking elexacaftor/tezacaftor/ivacaftor.
    Wood M; Babowicz F; Kennedy AG; Antell M; Gilhooly E; Tompkins BJ; Reddy SS
    J Am Pharm Assoc (2003); 2023; 63(3):920-924. PubMed ID: 36872183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
    Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA;
    Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of elexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry.
    Sutharsan S; Dillenhoefer S; Welsner M; Stehling F; Brinkmann F; Burkhart M; Ellemunter H; Dittrich AM; Smaczny C; Eickmeier O; Kappler M; Schwarz C; Sieber S; Naehrig S; Naehrlich L;
    Lancet Reg Health Eur; 2023 Sep; 32():100690. PubMed ID: 37554663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory T cell enhancement in adults with cystic fibrosis receiving Elexacaftor/Tezacaftor/Ivacaftor therapy.
    Westhölter D; Raspe J; Uebner H; Pipping J; Schmitz M; Straßburg S; Sutharsan S; Welsner M; Taube C; Reuter S
    Front Immunol; 2023; 14():1107437. PubMed ID: 36875141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The French Compassionate Program of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del
    Burgel PR; Sermet-Gaudelus I; Durieu I; Kanaan R; Macey J; Grenet D; Porzio M; Coolen-Allou N; Chiron R; Marguet C; Douvry B; Dufeu N; Danner-Boucher I; Foucaud P; Lemonnier L; Girodon E; Da Silva J; Martin C;
    Eur Respir J; 2023 Feb; ():. PubMed ID: 36796836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex differences in outcomes of people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor.
    Wang A; Lee M; Keller A; Jian S; Lowe K; Finklea JD; Jain R
    J Cyst Fibros; 2024 Jan; 23(1):91-98. PubMed ID: 37244841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis ineligible for clinical trials: a 24-week observational study.
    Fila L; Grandcourtova A; Bilkova A; Drevinek P
    Front Pharmacol; 2023; 14():1178009. PubMed ID: 37332357
    [No Abstract]   [Full Text] [Related]  

  • 15. Analyzing the use and impact of elexacaftor/tezacaftor/ivacaftor on total cost of care and other health care resource utilization in a commercially insured population.
    Smith S; Borchardt M
    J Manag Care Spec Pharm; 2022 Jul; 28(7):721-731. PubMed ID: 35737861
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment effects of Elexacaftor/Tezacaftor/Ivacaftor in people with CF carrying non-F508del mutations.
    Livnat G; Dagan A; Heching M; Shmueli E; Prais D; Yaacoby-Bianu K; Stein N; Mei-Zahav M; Gur M; Cohen-Cymberknoh M; Shteinberg M
    J Cyst Fibros; 2023 May; 22(3):450-455. PubMed ID: 36372699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multisystemic Effects of Elexacaftor-Tezacaftor-Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung Disease.
    Burgel PR; Paillasseur JL; Durieu I; Reynaud-Gaubert M; Hamidfar R; Murris-Espin M; Danner-Boucher I; Chiron R; Leroy S; Douvry B; Grenet D; Mely L; Ramel S; Montcouquiol S; Burnet E; Ouaalaya EH; Sogni P; Da Silva J; Martin C;
    Ann Am Thorac Soc; 2024 Jul; 21(7):1053-1064. PubMed ID: 38579175
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis.
    Scully KJ; Marchetti P; Sawicki GS; Uluer A; Cernadas M; Cagnina RE; Kennedy JC; Putman MS
    J Cyst Fibros; 2022 Mar; 21(2):258-263. PubMed ID: 34531155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gilbert's syndrome leads to elevated bilirubin after initiation of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis.
    Patel N; Ansar M; Pham A; Thomsen K; McKinzie CJ; Polineni D; Esther CR; Brown RF
    Pediatr Pulmonol; 2024 Apr; 59(4):863-866. PubMed ID: 38179880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lived experiences of people with cystic fibrosis that were not eligible for elexacaftor-tezacaftor-ivacaftor (ETI): A qualitative study.
    Milo F; Ciciriello F; Alghisi F; Tabarini P
    J Cyst Fibros; 2023 May; 22(3):414-419. PubMed ID: 36549989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.